Hoth Therapeutics, Inc. (HOTH) 10-Year Financial Performance & Capital Metrics

HOTH • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutHoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.Show more

Revenue $0
EBITDA $0
Net Income -$8M -4.4%
EPS (Diluted) -1.28 +44.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -99.75% +6.8%
ROIC -7169.46%
Debt/Equity 0.00 -21.9%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 1.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 87.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-59.77%

EPS CAGR

10Y-

5Y-

3Y-

TTM17.14%

ROCE

10Y Avg-233.5%

5Y Avg-146.51%

3Y Avg-115.26%

Latest-99.91%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-
Cost of Goods Sold+	188	28.25K	31.62K	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	-188	-28.25K	-31.62K	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-149.28%	-0.12%	1%	-	-	-	-
Operating Expenses+	1.87M	2.5M	7.71M	7.3M	14.1M	11.07M	7.69M	8.22M
OpEx % of Revenue	-	-	-	-	-	-	-	-
Selling, General & Admin	1.28M	1.22M	5.06M	4.41M	6.57M	6.13M	4.21M	4.97M
SG&A % of Revenue	-	-	-	-	-	-	-	-
Research & Development	586.84K	1.02M	2.12M	2.89M	7.53M	4.93M	3.48M	3.25M
R&D % of Revenue	-	-	-	-	-	-	-	-
Other Operating Expenses	0	258.71K	538.58K	0	0	0	0	0
Operating Income+	-1.87M	-2.5M	-7.71M	-7.3M	-14.1M	-11.07M	-7.69M	-8.22M
Operating Margin %	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-0.33%	-2.09%	0.05%	-0.93%	0.22%	0.3%	-0.07%
EBITDA+	-1.87M	-2.49M	-7.71M	-7.3M	-14.1M	0	0	0
EBITDA Margin %	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-0.33%	-2.09%	0.05%	-0.93%	1%	-	-
D&A (Non-Cash Add-back)	188	1.22K	1.23K	1.04K	0	11.07M	7.69M	8.22M
EBIT	-2.02M	-2.5M	-7.71M	-7.3M	-14.1M	-11.07M	-7.85M	-8.19M
Net Interest Income+	0	0	25	8	0	-299.04K	51.77K	27.71K
Interest Income	216K	0	25	8	0	6.37K	51.77K	27.71K
Interest Expense	0	0	0	0	0	305.41K	0	0
Other Income/Expense	-144K	0	10.36K	104.16K	-212.26K	-306.4K	-153.15K	27.13K
Pretax Income+	-2.02M	-2.5M	-7.7M	-7.2M	-14.31M	-11.37M	-7.85M	-8.19M
Pretax Margin %	-	-	-	-	-	-	-	-
Income Tax+	2	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-2.02M	-2.5M	-7.69M	-7.2M	-14.31M	-11.37M	-7.85M	-8.19M
Net Margin %	-	-	-	-	-	-	-	-
Net Income Growth %	-	-0.24%	-2.08%	0.06%	-0.99%	0.21%	0.31%	-0.04%
Net Income (Continuing)	-2.02M	-2.5M	-7.7M	-7.2M	-14.31M	-11.37M	-7.85M	-8.19M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-5.24	-6.62	-20.99	-14.56	-16.03	-9.50	-2.30	-1.28
EPS Growth %	-	-0.26%	-2.17%	0.31%	-0.1%	0.41%	0.76%	0.44%
EPS (Basic)	-5.24	-6.62	-20.99	-14.56	-16.03	-9.50	-2.30	-1.28
Diluted Shares Outstanding	384.48K	376.98K	366.58K	494.51K	893.2K	1.2M	3.41M	6.38M
Basic Shares Outstanding	384.48K	376.98K	366.58K	494.51K	893.2K	1.2M	3.41M	6.38M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.23M	501.65K	2.64M	4.78M	10.58M	6.73M	10.15M	7.64M
Cash & Short-Term Investments	1.23M	282.62K	2.49M	4.69M	10.43M	6.64M	9.29M	7.04M
Cash Only	1.23M	282.62K	1.69M	2.63M	8.54M	6.43M	9.29M	7.04M
Short-Term Investments	0	0	803.66K	2.06M	1.89M	209.32K	0	0
Accounts Receivable	0	0	0	0	50K	0	0	46.77K
Days Sales Outstanding	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	206.67K	30.48K	0	0	0	46.77K	0
Total Non-Current Assets+	3.49K	2.27K	201.04K	460K	410K	33K	92.56K	67.89K
Property, Plant & Equipment	3.49K	2.27K	1.04K	0	0	0	55.16K	31.07K
Fixed Asset Turnover	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	200K	410K	410K	33K	37.4K	36.82K
Other Non-Current Assets	0	0	0	50K	0	0	0	0
Total Assets+	1.23M	503.92K	2.84M	5.24M	10.99M	6.76M	10.24M	7.71M
Asset Turnover	-	-	-	-	-	-	-	-
Asset Growth %	-	-0.59%	4.63%	0.85%	1.1%	-0.38%	0.52%	-0.25%
Total Current Liabilities+	49.47K	348.95K	440.12K	312.15K	867.79K	1.39M	678.66K	831.2K
Accounts Payable	47.92K	142.28K	403.88K	129.47K	360.96K	694.99K	35.59K	412.07K
Days Payables Outstanding	93.04K	1.84K	4.66K	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	0	0	0	0	0
Current Ratio	24.87x	1.44x	5.99x	15.32x	12.19x	4.85x	14.96x	9.20x
Quick Ratio	24.87x	1.44x	5.99x	15.32x	12.19x	4.85x	14.96x	9.20x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	142.28K	0	285K	235K	250K	26.33K	2.71K
Long-Term Debt	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	26.33K	2.71K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	285K	235K	250K	0	0
Total Liabilities	49.47K	348.95K	440.12K	597.15K	1.1M	1.64M	704.98K	833.91K
Total Debt+	0	0	0	0	0	0	55.16K	31.07K
Net Debt	-1.23M	-282.62K	-1.69M	-2.63M	-8.54M	-6.43M	-9.24M	-7.01M
Debt / Equity	-	-	-	-	-	-	0.01x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-36.23x	-	-
Total Equity+	1.18M	154.97K	2.4M	4.65M	9.88M	5.12M	9.54M	6.88M
Equity Growth %	-	-0.87%	14.46%	0.94%	1.13%	-0.48%	0.86%	-0.28%
Book Value per Share	3.08	0.41	6.54	9.39	11.06	4.28	2.80	1.08
Total Shareholders' Equity	1.18M	154.97K	2.4M	4.65M	9.88M	5.12M	9.54M	6.88M
Common Stock	470	507	1.01K	1.34K	2.4K	130	435	804
Retained Earnings	-2.02M	-4.51M	-12.22M	-19.41M	-33.73M	-45.1M	-52.22M	-60.41M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	0	-310	0	-15.35K	17.59K	22.01K	27.26K	9.06K
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-465.24K	-2.1M	-4.95M	-6.13M	-12.09M	-9.3M	-8.45M	-6.98M
Operating CF Margin %	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-3.52%	-1.35%	-0.24%	-0.97%	0.23%	0.09%	0.17%
Net Income	-2.02M	-2.5M	-7.7M	-7.2M	-14.31M	-11.37M	-8.11M	-8.19M
Depreciation & Amortization	188	1.22K	1.23K	1.04K	0	0	0	0
Stock-Based Compensation	1.47M	143.05K	2.5M	737.75K	1.32M	620.8K	216.43K	804.28K
Deferred Taxes	0	0	-3.66K	-49.38K	0	0	0	0
Other Non-Cash Items	1.45M	168.16K	95K	506.96K	370.83K	858.82K	-70.08K	581
Working Capital Changes	49.47K	80.46K	169.64K	-131.75K	529.92K	594.48K	-487.32K	405.19K
Change in Receivables	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	47.92K	94.36K	267.36K	-151.99K	535.34K	590.63K	0	153.01K
Cash from Investing+	-303.68K	0	-895K	-1.84M	-165.35K	1.16M	0	0
Capital Expenditures	-303.68K	0	-95K	-167.46K	-116.97K	-74K	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	-450K	0	0	-50K	-116.97K	0	0	0
Cash from Financing+	2M	1.15M	7.45M	8.73M	18.19M	6.04M	11.32M	4.74M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	9K	1.15M	163	56.25K	359.51K	50K	2.35K	3.68M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-768.92K	-2.1M	-5.04M	-6.3M	-12.21M	-9.37M	-8.45M	-6.98M
FCF Margin %	-	-	-	-	-	-	-	-
FCF Growth %	-	-1.73%	-1.4%	-0.25%	-0.94%	0.23%	0.1%	0.17%
FCF per Share	-2.00	-5.58	-13.75	-12.74	-13.67	-7.83	-2.48	-1.09
FCF Conversion (FCF/Net Income)	0.23x	0.84x	0.64x	0.85x	0.84x	0.82x	1.08x	0.85x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-170.16%	-372.62%	-603.24%	-204.44%	-197.05%	-151.59%	-107.03%	-99.75%
Return on Invested Capital (ROIC)	-	-	-2003.94%	-402.52%	-629.54%	-44786.52%	-	-7169.46%
Debt / Equity	-	-	-	-	-	-	0.01x	0.00x
Interest Coverage	-	-	-	-	-	-36.23x	-	-
FCF Conversion	0.23x	0.84x	0.64x	0.85x	0.84x	0.82x	1.08x	0.85x

Frequently Asked Questions

Growth & Financials

Hoth Therapeutics, Inc. (HOTH) grew revenue by 0.0% over the past year. Growth has been modest.

Hoth Therapeutics, Inc. (HOTH) reported a net loss of $12.2M for fiscal year 2024.

Dividend & Returns

Hoth Therapeutics, Inc. (HOTH) has a return on equity (ROE) of -99.8%. Negative ROE indicates the company is unprofitable.

Hoth Therapeutics, Inc. (HOTH) had negative free cash flow of $9.7M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

Hoth Therapeutics, Inc. (HOTH) 10-Year Financial Performance & Capital Metrics

HOTH • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $0
EBITDA $0
Net Income -$8M -4.4%
EPS (Diluted) -1.28 +44.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -99.75% +6.8%
ROIC -7169.46%
Debt/Equity 0.00 -21.9%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 1.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 87.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-59.77%

EPS CAGR

10Y-

5Y-

3Y-

TTM17.14%

ROCE

10Y Avg-233.5%

5Y Avg-146.51%

3Y Avg-115.26%

Latest-99.91%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-
Cost of Goods Sold+	188	28.25K	31.62K	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	-188	-28.25K	-31.62K	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-149.28%	-0.12%	1%	-	-	-	-
Operating Expenses+	1.87M	2.5M	7.71M	7.3M	14.1M	11.07M	7.69M	8.22M
OpEx % of Revenue	-	-	-	-	-	-	-	-
Selling, General & Admin	1.28M	1.22M	5.06M	4.41M	6.57M	6.13M	4.21M	4.97M
SG&A % of Revenue	-	-	-	-	-	-	-	-
Research & Development	586.84K	1.02M	2.12M	2.89M	7.53M	4.93M	3.48M	3.25M
R&D % of Revenue	-	-	-	-	-	-	-	-
Other Operating Expenses	0	258.71K	538.58K	0	0	0	0	0
Operating Income+	-1.87M	-2.5M	-7.71M	-7.3M	-14.1M	-11.07M	-7.69M	-8.22M
Operating Margin %	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-0.33%	-2.09%	0.05%	-0.93%	0.22%	0.3%	-0.07%
EBITDA+	-1.87M	-2.49M	-7.71M	-7.3M	-14.1M	0	0	0
EBITDA Margin %	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-0.33%	-2.09%	0.05%	-0.93%	1%	-	-
D&A (Non-Cash Add-back)	188	1.22K	1.23K	1.04K	0	11.07M	7.69M	8.22M
EBIT	-2.02M	-2.5M	-7.71M	-7.3M	-14.1M	-11.07M	-7.85M	-8.19M
Net Interest Income+	0	0	25	8	0	-299.04K	51.77K	27.71K
Interest Income	216K	0	25	8	0	6.37K	51.77K	27.71K
Interest Expense	0	0	0	0	0	305.41K	0	0
Other Income/Expense	-144K	0	10.36K	104.16K	-212.26K	-306.4K	-153.15K	27.13K
Pretax Income+	-2.02M	-2.5M	-7.7M	-7.2M	-14.31M	-11.37M	-7.85M	-8.19M
Pretax Margin %	-	-	-	-	-	-	-	-
Income Tax+	2	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-2.02M	-2.5M	-7.69M	-7.2M	-14.31M	-11.37M	-7.85M	-8.19M
Net Margin %	-	-	-	-	-	-	-	-
Net Income Growth %	-	-0.24%	-2.08%	0.06%	-0.99%	0.21%	0.31%	-0.04%
Net Income (Continuing)	-2.02M	-2.5M	-7.7M	-7.2M	-14.31M	-11.37M	-7.85M	-8.19M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-5.24	-6.62	-20.99	-14.56	-16.03	-9.50	-2.30	-1.28
EPS Growth %	-	-0.26%	-2.17%	0.31%	-0.1%	0.41%	0.76%	0.44%
EPS (Basic)	-5.24	-6.62	-20.99	-14.56	-16.03	-9.50	-2.30	-1.28
Diluted Shares Outstanding	384.48K	376.98K	366.58K	494.51K	893.2K	1.2M	3.41M	6.38M
Basic Shares Outstanding	384.48K	376.98K	366.58K	494.51K	893.2K	1.2M	3.41M	6.38M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.23M	501.65K	2.64M	4.78M	10.58M	6.73M	10.15M	7.64M
Cash & Short-Term Investments	1.23M	282.62K	2.49M	4.69M	10.43M	6.64M	9.29M	7.04M
Cash Only	1.23M	282.62K	1.69M	2.63M	8.54M	6.43M	9.29M	7.04M
Short-Term Investments	0	0	803.66K	2.06M	1.89M	209.32K	0	0
Accounts Receivable	0	0	0	0	50K	0	0	46.77K
Days Sales Outstanding	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	206.67K	30.48K	0	0	0	46.77K	0
Total Non-Current Assets+	3.49K	2.27K	201.04K	460K	410K	33K	92.56K	67.89K
Property, Plant & Equipment	3.49K	2.27K	1.04K	0	0	0	55.16K	31.07K
Fixed Asset Turnover	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	200K	410K	410K	33K	37.4K	36.82K
Other Non-Current Assets	0	0	0	50K	0	0	0	0
Total Assets+	1.23M	503.92K	2.84M	5.24M	10.99M	6.76M	10.24M	7.71M
Asset Turnover	-	-	-	-	-	-	-	-
Asset Growth %	-	-0.59%	4.63%	0.85%	1.1%	-0.38%	0.52%	-0.25%
Total Current Liabilities+	49.47K	348.95K	440.12K	312.15K	867.79K	1.39M	678.66K	831.2K
Accounts Payable	47.92K	142.28K	403.88K	129.47K	360.96K	694.99K	35.59K	412.07K
Days Payables Outstanding	93.04K	1.84K	4.66K	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	0	0	0	0	0
Current Ratio	24.87x	1.44x	5.99x	15.32x	12.19x	4.85x	14.96x	9.20x
Quick Ratio	24.87x	1.44x	5.99x	15.32x	12.19x	4.85x	14.96x	9.20x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	142.28K	0	285K	235K	250K	26.33K	2.71K
Long-Term Debt	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	26.33K	2.71K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	285K	235K	250K	0	0
Total Liabilities	49.47K	348.95K	440.12K	597.15K	1.1M	1.64M	704.98K	833.91K
Total Debt+	0	0	0	0	0	0	55.16K	31.07K
Net Debt	-1.23M	-282.62K	-1.69M	-2.63M	-8.54M	-6.43M	-9.24M	-7.01M
Debt / Equity	-	-	-	-	-	-	0.01x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-36.23x	-	-
Total Equity+	1.18M	154.97K	2.4M	4.65M	9.88M	5.12M	9.54M	6.88M
Equity Growth %	-	-0.87%	14.46%	0.94%	1.13%	-0.48%	0.86%	-0.28%
Book Value per Share	3.08	0.41	6.54	9.39	11.06	4.28	2.80	1.08
Total Shareholders' Equity	1.18M	154.97K	2.4M	4.65M	9.88M	5.12M	9.54M	6.88M
Common Stock	470	507	1.01K	1.34K	2.4K	130	435	804
Retained Earnings	-2.02M	-4.51M	-12.22M	-19.41M	-33.73M	-45.1M	-52.22M	-60.41M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	0	-310	0	-15.35K	17.59K	22.01K	27.26K	9.06K
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-465.24K	-2.1M	-4.95M	-6.13M	-12.09M	-9.3M	-8.45M	-6.98M
Operating CF Margin %	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-3.52%	-1.35%	-0.24%	-0.97%	0.23%	0.09%	0.17%
Net Income	-2.02M	-2.5M	-7.7M	-7.2M	-14.31M	-11.37M	-8.11M	-8.19M
Depreciation & Amortization	188	1.22K	1.23K	1.04K	0	0	0	0
Stock-Based Compensation	1.47M	143.05K	2.5M	737.75K	1.32M	620.8K	216.43K	804.28K
Deferred Taxes	0	0	-3.66K	-49.38K	0	0	0	0
Other Non-Cash Items	1.45M	168.16K	95K	506.96K	370.83K	858.82K	-70.08K	581
Working Capital Changes	49.47K	80.46K	169.64K	-131.75K	529.92K	594.48K	-487.32K	405.19K
Change in Receivables	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	47.92K	94.36K	267.36K	-151.99K	535.34K	590.63K	0	153.01K
Cash from Investing+	-303.68K	0	-895K	-1.84M	-165.35K	1.16M	0	0
Capital Expenditures	-303.68K	0	-95K	-167.46K	-116.97K	-74K	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	-450K	0	0	-50K	-116.97K	0	0	0
Cash from Financing+	2M	1.15M	7.45M	8.73M	18.19M	6.04M	11.32M	4.74M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	9K	1.15M	163	56.25K	359.51K	50K	2.35K	3.68M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-768.92K	-2.1M	-5.04M	-6.3M	-12.21M	-9.37M	-8.45M	-6.98M
FCF Margin %	-	-	-	-	-	-	-	-
FCF Growth %	-	-1.73%	-1.4%	-0.25%	-0.94%	0.23%	0.1%	0.17%
FCF per Share	-2.00	-5.58	-13.75	-12.74	-13.67	-7.83	-2.48	-1.09
FCF Conversion (FCF/Net Income)	0.23x	0.84x	0.64x	0.85x	0.84x	0.82x	1.08x	0.85x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-170.16%	-372.62%	-603.24%	-204.44%	-197.05%	-151.59%	-107.03%	-99.75%
Return on Invested Capital (ROIC)	-	-	-2003.94%	-402.52%	-629.54%	-44786.52%	-	-7169.46%
Debt / Equity	-	-	-	-	-	-	0.01x	0.00x
Interest Coverage	-	-	-	-	-	-36.23x	-	-
FCF Conversion	0.23x	0.84x	0.64x	0.85x	0.84x	0.82x	1.08x	0.85x

Frequently Asked Questions

Growth & Financials

Hoth Therapeutics, Inc. (HOTH) grew revenue by 0.0% over the past year. Growth has been modest.

Hoth Therapeutics, Inc. (HOTH) reported a net loss of $12.2M for fiscal year 2024.

Dividend & Returns

Hoth Therapeutics, Inc. (HOTH) has a return on equity (ROE) of -99.8%. Negative ROE indicates the company is unprofitable.

Hoth Therapeutics, Inc. (HOTH) had negative free cash flow of $9.7M in fiscal year 2024, likely due to heavy capital investments.